India · Delayed Price · Currency is INR Windlas Biotech Statistics
Total Valuation
Windlas Biotech has a market cap or net worth of INR 17.13 billion. The enterprise value is 14.69 billion.
| Market Cap | 17.13B |
| Enterprise Value | 14.69B |
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Jul 16, 2026 |
Share Statistics
Windlas Biotech has 20.64 million shares outstanding. The number of shares has increased by 0.98% in one year.
| Current Share Class | 20.64M |
| Shares Outstanding | 20.64M |
| Shares Change (YoY) | +0.98% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 63.38% |
| Owned by Institutions (%) | 9.07% |
| Float | 7.27M |
Valuation Ratios
The trailing PE ratio is 26.64.
| PE Ratio | 26.64 |
| Forward PE | n/a |
| PS Ratio | 1.89 |
| PB Ratio | 2.95 |
| P/TBV Ratio | 2.98 |
| P/FCF Ratio | 45.95 |
| P/OCF Ratio | 16.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.19, with an EV/FCF ratio of 39.42.
| EV / Earnings | 22.11 |
| EV / Sales | 1.62 |
| EV / EBITDA | 14.19 |
| EV / EBIT | 19.85 |
| EV / FCF | 39.42 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.95 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 0.95 |
| Interest Coverage | 15.33 |
Financial Efficiency
Return on equity (ROE) is 12.23% and return on invested capital (ROIC) is 17.62%.
| Return on Equity (ROE) | 12.23% |
| Return on Assets (ROA) | 5.55% |
| Return on Invested Capital (ROIC) | 17.62% |
| Return on Capital Employed (ROCE) | 12.62% |
| Weighted Average Cost of Capital (WACC) | 5.84% |
| Revenue Per Employee | 6.53M |
| Profits Per Employee | 479,827 |
| Employee Count | 1,385 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 7.84 |
Taxes
In the past 12 months, Windlas Biotech has paid 205.21 million in taxes.
| Income Tax | 205.21M |
| Effective Tax Rate | 23.59% |
Stock Price Statistics
The stock price has decreased by -10.54% in the last 52 weeks. The beta is 0.27, so Windlas Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -10.54% |
| 50-Day Moving Average | 824.35 |
| 200-Day Moving Average | 825.10 |
| Relative Strength Index (RSI) | 46.80 |
| Average Volume (20 Days) | 48,158 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Windlas Biotech had revenue of INR 9.04 billion and earned 664.56 million in profits. Earnings per share was 31.15.
| Revenue | 9.04B |
| Gross Profit | 3.43B |
| Operating Income | 739.99M |
| Pretax Income | 869.77M |
| Net Income | 664.56M |
| EBITDA | 1.01B |
| EBIT | 739.99M |
| Earnings Per Share (EPS) | 31.15 |
Balance Sheet
The company has 2.79 billion in cash and 352.42 million in debt, with a net cash position of 2.44 billion or 118.03 per share.
| Cash & Cash Equivalents | 2.79B |
| Total Debt | 352.42M |
| Net Cash | 2.44B |
| Net Cash Per Share | 118.03 |
| Equity (Book Value) | 5.81B |
| Book Value Per Share | 275.20 |
| Working Capital | 3.06B |
Cash Flow
In the last 12 months, operating cash flow was 1.05 billion and capital expenditures -676.64 million, giving a free cash flow of 372.70 million.
| Operating Cash Flow | 1.05B |
| Capital Expenditures | -676.64M |
| Depreciation & Amortization | 267.70M |
| Net Borrowing | -940,000 |
| Free Cash Flow | 372.70M |
| FCF Per Share | 18.06 |
Margins
Gross margin is 37.92%, with operating and profit margins of 8.18% and 7.35%.
| Gross Margin | 37.92% |
| Operating Margin | 8.18% |
| Pretax Margin | 9.62% |
| Profit Margin | 7.35% |
| EBITDA Margin | 11.15% |
| EBIT Margin | 8.18% |
| FCF Margin | 4.12% |
Dividends & Yields
This stock pays an annual dividend of 6.30, which amounts to a dividend yield of 0.76%.
| Dividend Per Share | 6.30 |
| Dividend Yield | 0.76% |
| Dividend Growth (YoY) | 8.62% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 18.29% |
| Buyback Yield | -0.98% |
| Shareholder Yield | -0.22% |
| Earnings Yield | 3.88% |
| FCF Yield | 2.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Windlas Biotech has an Altman Z-Score of 5.62 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.62 |
| Piotroski F-Score | 5 |